<VariationArchive VariationID="2571592" VariationName="NM_000512.5(GALNS):c.423-11_425del" VariationType="Deletion" Accession="VCV002571592" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-20" DateCreated="2023-07-17" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2736544" VariationID="2571592">
      <GeneList>
        <Gene Symbol="GALNS" FullName="galactosamine (N-acetyl)-6-sulfatase" GeneID="2588" HGNC_ID="HGNC:4122" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16q24.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="88813734" stop="88856947" display_start="88813734" display_stop="88856947" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="88880141" stop="88923373" display_start="88880141" display_stop="88923373" Strand="-" />
          </Location>
          <OMIM>612222</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000512.5(GALNS):c.423-11_425del</Name>
      <CanonicalSPDI>NC_000016.10:88837762:TGCCTGGAAACAGG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16q24.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="88837763" stop="88837776" display_start="88837763" display_stop="88837776" variantLength="14" positionVCF="88837762" referenceAlleleVCF="ATGCCTGGAAACAGG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="88904171" stop="88904184" display_start="88904171" display_stop="88904184" variantLength="14" positionVCF="88904170" referenceAlleleVCF="ATGCCTGGAAACAGG" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>p.Trp141CysfsTer3</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.88837763_88837776del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.88837763_88837776del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.88904171_88904184del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.88904171_88904184del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008667.1" sequenceAccession="NG_008667" sequenceVersion="1" change="g.24191_24204del">
            <Expression>NG_008667.1:g.24191_24204del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001323543.2" sequenceAccession="NM_001323543" sequenceVersion="2" change="c.-133-11_-131del">
            <Expression>NM_001323543.2:c.-133-11_-131del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000512.5" sequenceAccession="NM_000512" sequenceVersion="5" change="c.423-11_425del" MANESelect="true">
            <Expression>NM_000512.5:c.423-11_425del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001323544.2" sequenceAccession="NM_001323544" sequenceVersion="2" change="c.441-11_443del">
            <Expression>NM_001323544.2:c.441-11_443del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000512.5(GALNS):c.423-11_425del AND Mucopolysaccharidosis, MPS-IV-A" Accession="RCV003312991" Version="2">
        <ClassifiedConditionList TraitSetID="175">
          <ClassifiedCondition DB="MedGen" ID="C0086651">Mucopolysaccharidosis, MPS-IV-A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-08-29" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-29" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2023-07-17" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12442278</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20574428</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25252036</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25545067</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29731656</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30094185</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="175" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3036" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome A, mild</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-A</ElementValue>
                <XRef ID="Morquio+syndrome+A/4876" DB="Genetic Alliance" />
                <XRef ID="7259005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVA</ElementValue>
                <XRef Type="MIM" ID="253000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio A disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactosamine-6-sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVA</ElementValue>
                <XRef ID="NBK148668" DB="GeneReviews" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4A</ElementValue>
                <XRef Type="MIM" ID="253000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The phenotypic spectrum of mucopolysaccharidosis IVA (MPS IVA) is a continuum that ranges from a severe and rapidly progressive early-onset form to a slowly progressive later-onset form. Children with MPS IVA typically have no distinctive clinical findings at birth. The severe form is usually apparent between ages one and three years, often first manifesting as kyphoscoliosis, genu valgum (knock-knee), and pectus carinatum; the slowly progressive form may not become evident until late childhood or adolescence, often first manifesting as hip problems (pain, stiffness, and Legg Perthes disease). Progressive bone and joint involvement leads to short stature, and eventually to disabling pain and arthritis. Involvement of other organ systems can lead to significant morbidity, including respiratory compromise, obstructive sleep apnea, valvular heart disease, hearing impairment, visual impairment from corneal clouding, dental abnormalities, and hepatomegaly. Compression of the spinal cord is a common complication that results in neurologic impairment. Children with MPS IVA have normal intellectual abilities at the outset of the disease.</Attribute>
                <XRef ID="NBK148668" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3785" />
                <XRef ID="3785" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23844448</ID>
                <ID Source="BookShelf">NBK148668</ID>
              </Citation>
              <XRef ID="309297" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086651" DB="MedGen" />
              <XRef ID="MONDO:0009659" DB="MONDO" />
              <XRef Type="MIM" ID="253000" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7508587" SubmissionDate="2023-07-10" DateLastUpdated="2023-07-16" DateCreated="2023-07-16">
        <ClinVarSubmissionID localKey="SUB13654509" submittedAssembly="GRCh38" title="SUB13654509" />
        <ClinVarAccession Accession="SCV004011718" DateUpdated="2023-07-16" DateCreated="2023-07-16" Type="SCV" Version="1" SubmitterName="Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics" OrgID="505565" OrganizationCategory="other" OrgAbbreviation="FRIGE - IHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>A homozygous 14 base pair deletion in Intron 4 of the GALNS gene that results in a frameshift and premature truncation of the protein 382 amino acids downstream to codon 141 was detected. The observed variant c.423-11_425del (p.Trp141CysfsTer382) in intron has not been reported in the 1000 genomes and gnomAD databases. The in-silico prediction of the variant is disease causing by Mutation Taster. In summary, the variant meets our criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina sequencing platform</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>DNA extracted from blood was used to perform targeted gene capture using a custom smMIP panel. The libraries were sequenced to mean &gt;100-300X coverage on the Illumina MiSeq sequencing platform. The sequences obtained are aligned to the human reference genome (GRCh37) using the BWA program and analyzed using Picard and GATK version 4.1.2 to identify variants relevant to the clinical indication.</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2023-06-03" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000926" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALNS">
              <Name>galactosamine (N-acetyl)-6-sulfatase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000512.5:intron 4</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Trp141CysfsTer3</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000512.5:c.423-11_425del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="253000" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13654509</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8005158" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="27087864|MedGen:C0086651" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004320563" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20574428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25252036</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25545067</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29731656</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30094185</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12442278</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the GALNS protein in which other variant(s) (p.His142Leu) have been determined to be pathogenic (PMID: 20574428, 25252036, 25545067, 29731656, 30094185). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 2571592). This variant has not been reported in the literature in individuals affected with GALNS-related conditions. This variant is not present in population databases (gnomAD no frequency). This variant results in the deletion of part of exon 5 (c.423-11_425del) of the GALNS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALNS are known to be pathogenic (PMID: 12442278).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.88904171_88904184del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086651" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7508587" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000926" MappingRef="HP">
        <MedGen CUI="C1844704" Name="Platyspondyly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8005158" TraitType="Disease" MappingType="XRef" MappingValue="C0086651" MappingRef="MedGen">
        <MedGen CUI="C0086651" Name="Mucopolysaccharidosis, MPS-IV-A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7508587" TraitType="Disease" MappingType="XRef" MappingValue="253000" MappingRef="OMIM">
        <MedGen CUI="C0086651" Name="Mucopolysaccharidosis, MPS-IV-A" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

